Denmark has banned the Oxford-AstraZeneca covid vaccine amid growing threats of the coronavirus. It has also become the first country in Europe to impose such a ban. Previously, many European countries have already discontinued it for some time on suspicion of blood clotting after the vaccine was given, although the vaccine is still being applied in those countries.
Denmark’s vaccination program may get a shock
Denmark has imposed this ban after blood clots have formed in the body of some people after being given the vaccine. However, experts claim that such incidents are quite rare. It is being told that this step may give a major blow to the vaccination program released in Denmark. Currently, AstraZeneca’s 2.4 million Covid vaccines in Denmark is present at several centers, which are now being withdrawn.
Officials told why to ban
Danish health officials have claimed that cases of blood clots from AstraZeneca’s vaccine are more than expected. Therefore, we have decided to ban the use of this vaccine with immediate effect. According to an estimate, two out of 40,000 people in Denmark are experiencing blood clots after vaccination.
1 million people were vaccinated in Denmark
In Denmark, vaccines have been administered to one million people so far. Of these, one and a half million people have been vaccinated with AstraZeneca. Being a member of the European Union, all the vaccines approved by the European Medical Agency can be applied in this country too. In which, if AstraZeneca is eliminated, Pfizer and Moderna’s Covid vaccine is the main one.
European agency also accepted the relation of vaccine and blood clots
Europe’s drug regulatory body European Medical Agency (EMA) reported a few days ago that it had found a possible connection between AstraZeneca’s coronavirus vaccine and a rare blood clotting problem. However, he claimed that the benefits of this vaccine still outweigh the risks. Marco Cavalleri, head of the agency’s Health Risk and Vaccine Strategy, said that it is becoming very difficult to say that there is no causal contact between AstraZeneca vaccines and extremely rare blood clots associated with platelet depletion. The agency stated that its evaluation has not yet reached a conclusion and is currently under review.